Frank Leonard is recorded as Board Member at NovoCure Ltd (NVCR) since June 3, 2026 and CEO at NovoCure Ltd (NVCR). The newest filing on record that lists Frank Leonard as CEO at NovoCure Ltd (NVCR) is dated April 20, 2026. NovoCure Ltd reported in an 8-K filed June 5, 2026 that Frank Leonard was appointed director, effective June 3, 2026. NovoCure Ltd reported in an 8-K filed December 1, 2025 that Frank Leonard was appointed Chief Executive Officer, effective December 1, 2025. NovoCure Ltd reported in an 8-K filed January 4, 2024 that Frank Leonard was appointed Executive Vice President and President, Novocure Oncology, effective January 1, 2024. The proxy statement of NovoCure Ltd reports total compensation of $6,975,329 for Frank Leonard in fiscal 2025, including a base salary of $570,000. Disclosed compensation is on record for 3 fiscal years. Frank Leonard has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for NovoCure Ltd on October 29, 2026. NovoCure Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at NovoCure Ltd includes Asaf Danziger (CEO and Board Member), David Hung (CEO and Board Member), William Vernon (CEO and Board Member) and 7 others.
“The Company’s shareholders elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Frank Leonard, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2027.”
“On December 1, 2025, the Company announced the appointment of Frank Leonard, age 46, who is currently serving as the Company's President, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the "Novocure Group"), effective December 1, 2025.”
NovoCure Ltd Form 8-K, filed December 1, 2025
· Read the filing
Frank Leonard on recent calls
“We believe that we have multiple drivers of long-term growth, including increasing adoption of Optune Geo, successfully launching new indications like Optune Pax and Maya, and pursuing opportunistic launches, such as the Optune Lua launch in Japan.”
“Yeah, happy to provide an update and also just want to start by saying thank you to you and to Wells Fargo for covering us with Larry for so many years and really being very detailed in your coverage of Novacure.”
“We are entering a new phase of clinical development at Novocure. Historically, our clinical strategy has focused on areas of significant unmet need and opportunities to establish TT fields in new cancer types.”
“Our Optune Geo business remains the core driver of our commercial portfolio. We are off to a strong start to the year, with 9% year-over-year growth in active patients We saw our strongest growth in Japan, Germany, and France, which contributed 20%, 12%, and 9% year-over-year active patient growth, respectively.”
“I'm excited to speak to you in my new role as CEO and at a time when NovaCure is evolving into a multi-indication platform company. 2025 was our most successful commercial year to date, and we expect to carry this positive momentum into 2026.”
